Moderna has completed enrollment for a Phase 2/3 trial studying their vaccine in adolescents and will start the Phase 2 study in younger children soon, the company said in a press release Thursday.
“TeenCOVE,” the study of mRNA-1273 in adolescents ages 12 to 17, completed Phase 2/3 enrollment of 3,000 US participants.
Phase 2 “KidCOVE,” Moderna’s study of the vaccine in younger children, ages 6 months to 11 years, will start in the near term, the release said.
The release also updated on a next-generation vaccine against Covid-19, called mRNA-1283, which is being developed as a “potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration.”
This next generation vaccine is intended to be evaluated for use as a booster dose for those who have previously been vaccinated or infected as well as a primary series for those who are have not had Covid-19 and have yet to be vaccinated.
Moderna is one of two companies with Covid-19 vaccines authorized for emergency use in the United States.